Antenatal and newborn screening KPI data: Q2 summary factsheets
Updated 10 October 2024
© Crown copyright 2024
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/nhs-screening-programmes-kpi-reports-2020-to-2021/antenatal-and-newborn-screening-kpi-data-q2-summary-factsheets
Please be aware that this data covers the period through the coronavirus (COVID-19) pandemic. Provider performance should therefore be interpreted with caution.
In addition to this, some providers were justifiably not able to make timely data returns or validate their data in this period. We recommend looking at the historical trend data of services before the COVID-19 pandemic to help interpret the data.
1. Fetal anomaly (FA) screening
1.1 KPI FA2: coverage – fetal anomaly ultrasound
National performance of FA2 in Q1 2020 to 2021 was 99.3%, the highest ever level recorded for this key performance indicator (KPI0. FA2 is collected 6 months (2 quarters) in arrears. The national trend graph below shows that FA2 performance has remained above the achievable threshold of 95% since 1 April 2017.
All screening services which submitted data (140 out of 142) met the acceptable threshold of 90%. One hundred and thirty-nine services met the achievable threshold of 95% and 39 of them reported performance of 100%.
Quarter 1 performance
| Reporting period | 1 April to 30 June 2020 |
|---|---|
| Numerator | 135,218 |
| Denominator | 136,228 |
| Performance | 99.3% |
| Completeness of data | 98.6% |
| Region | Performance % |
|---|---|
| London | 99.2% |
| Midlands and East | 99.4% |
| North | 99.3% |
| South | 99.2% |
| England | 99.3% |
1.2 KPI FA3
There is no intention to publish FA3 by individual maternity service. We are reviewing the data with the aim of publishing it nationally in the future.
In Q2, 138 out of 142 screening services submitted data.
1.3 KPI FA4
FA4 was introduced in 2020 to 2021. New KPIs are not published in the first year of data collection. This time is used to improve the data quality and completeness by revising the definition, adding clarity or setting thresholds as required. After this time, we will review the data with the aim of publishing it from the following year.
2. Infectious diseases (IDs) in pregnancy screening
2.1 KPI ID1: HIV coverage
National performance of ID1 in Q2 was 99.8%, the highest ever level recorded for this KPI. The national trend graph below shows that ID1 performance has remained above the achievable threshold of 99% since 1 April 2017.
All 142 screening services submitted data, and all of them reached the achievable threshold of 99%.
Twenty-eight screening services reported performance of 100%.
Quarter 2 performance
| Reporting period | 1 July to 30 September 2020 |
|---|---|
| Numerator | 158,284 |
| Denominator | 158,611 |
| Performance | 99.8% |
| Completeness of data | 100% |
| Region | Performance % |
|---|---|
| London | 99.8% |
| Midlands and East | 99.8% |
| North | 99.7% |
| South | 99.8% |
| England | 99.8% |
2.2 KPI ID2: diagnosis/intervention – timely assessment of women with hepatitis B
National performance of ID2 in Q2 was 88.2%. The national trend graph below shows that ID2 performance has remained above the acceptable threshold of 70% since 1 April 2017.
All 142 screening services submitted data, including 65 services that reported zero women. Of the remaining 77 services, 61 met the acceptable threshold. ID2 is a small number KPI, therefore the data should be interpreted with caution.
Quarter 2 performance
| Reporting period | 1 July to 30 September 2020 |
|---|---|
| Numerator | 179 |
| Denominator | 203 |
| Performance | 88.2% |
| Completeness of data | 100% |
| Region | Performance % |
|---|---|
| London | 87.8% |
| Midlands and East | 86.7% |
| North | 89.4% |
| South | 90.9% |
| England | 88.2% |
2.3 KPI ID3: coverage – hepatitis B
National performance of ID3 in Q2 was 99.8%, slightly higher than the previous 2 quarters. The national trend graph below shows that ID3 performance has remained above the achievable threshold of 99% since 1 April 2018 when it was first introduced.
All 142 screening services submitted data, and all of them met the acceptable threshold of 95%.
One hundred and forty-one screening services reached the achievable threshold of 99%, and 28 of them reported performance of 100%.
Quarter 2 performance
| Reporting period | 1 July to 30 September 2020 |
|---|---|
| Numerator | 158,285 |
| Denominator | 158,608 |
| Performance | 99.8% |
| Completeness of data | 100% |
| Region | Performance % |
|---|---|
| London | 99.8% |
| Midlands and East | 99.8% |
| North | 99.7% |
| South | 99.8% |
| England | 99.8% |
2.4 KPI ID4: coverage – syphilis
National performance of ID4 in Q2 was 99.8%, higher than the previous 2 quarters. The national trend graph below shows that ID4 performance has remained above the achievable threshold of 99% since 1 April 2018 when it was first introduced.
All 142 screening services submitted data, and all of them reached the achievable threshold of 99%.
Twenty-eight screening services reported performance of 100%.
Quarter 2 performance
| Reporting period | 1 July to 30 September 2020 |
|---|---|
| Numerator | 158,281 |
| Denominator | 158,606 |
| Performance | 99.8% |
| Completeness of data | 100% |
| Region | Performance % |
|---|---|
| London | 99.8% |
| Midlands and East | 99.8% |
| North | 99.7% |
| South | 99.8% |
| England | 99.8% |
3. Sickle cell and thalassaemia screening
3.1 KPI ST1: coverage – antenatal screening
National performance of ST1 in Q2 was 99.7%. The national trend graph below shows that ST1 performance has remained above the achievable threshold of 99% since 1 April 2017.
All 142 screening services submitted data, and all of them met the acceptable threshold of 95%.
One hundred and thirty-six screening services reached the achievable threshold of 99%, and 27 of them reported performance of 100%.
Quarter 2 performance
| Reporting period | 1 July to 30 September 2020 |
|---|---|
| Numerator | 158,118 |
| Denominator | 158,550 |
| Performance | 99.7% |
| Completeness of data | 100% |
| Region | Performance % |
|---|---|
| London | 99.8% |
| Midlands and East | 99.8% |
| North | 99.6% |
| South | 99.7% |
| England | 99.7% |
3.2 KPI ST2: test – timeliness of antenatal screening
National performance of ST2 in Q2 was 49.1%. The national trend graph below shows that ST2 performance has dropped below the acceptable threshold of 50% for Q1 and Q2 of 2020 to 2021.
Data suggests that while services were maintained, performance was affected for this KPI during COVID-19. This is not unexpected as technical guidance in place at the time stated that services could offer screening later than 10 weeks.
One hundred and thirty-eight out of 142 screening services submitted data for this KPI for Q2.
Quarter 2 performance
| Reporting period | 1 July to 30 September 2020 |
|---|---|
| Numerator | 79,129 |
| Denominator | 161,075 |
| Performance | 49.1% |
| Completeness of data | 97.2% |
| Region | Performance % |
|---|---|
| London | 32.0% |
| Midlands and East | 49.5% |
| North | 60.0% |
| South | 50.4% |
| England | 49.1% |
3.3 KPI ST3: test – timeliness of antenatal screening
National performance of ST3 in Q2 was 97.5%. The national trend graph below shows that ST3 performance has remained above the acceptable threshold of 95% since 1 April 2017.
All 142 screening services submitted data, and 127 met the acceptable threshold.
Sixty-two services met the achievable threshold of 99%, and 16 of them reported 100%.
Quarter 2 performance
| Reporting period | 1 July to 30 September 2020 |
|---|---|
| Numerator | 161,976 |
| Denominator | 166,193 |
| Performance | 97.5% |
| Completeness of data | 100% |
| Region | Performance % |
|---|---|
| London | 96.3% |
| Midlands and East | 98.2 % |
| North | 97.3% |
| South | 97.8% |
| England | 97.5% |
3.4 KPI ST4a: referral – timely offer of prenatal diagnosis (PND) to women at risk of having an infant with sickle cell disease or thalassaemia
National performance of ST4a in Q2 was 44.4%. The national trend graph below shows the ST4a performance since the KPI was first published from 1 April 2019. Thresholds have not yet been set for this KPI.
All 142 screening services submitted data, including 66 services that reported zero women at risk.
We have identified quality issues with the submitted data, therefore we recommend that regional performance is not compared. We share screening service level data with NHS England and NHS Improvement and we’re reviewing this KPI with the aim of improving data quality.
Quarter 2 performance
| Reporting period | 1 July to 30 September 2020 |
|---|---|
| Numerator | 220 |
| Denominator | 496 |
| Performance | 44.4% |
| Completeness of data | 100% |
| Region | Performance % |
|---|---|
| London | 41.5% |
| Midlands and East | 45.5% |
| North | 56.3% |
| South | 54.1% |
| England | 44.4% |
3.5 KPI ST4b: referral – timely offer of prenatal diagnosis (PND) to couples at risk of having an infant with sickle cell disease or thalassaemia
National performance of ST4b in Q2 was 61.9%. The national trend graph below shows the ST4b performance since the KPI was first published from 1 April 2019. Thresholds have not yet been set for this KPI.
All 142 screening services submitted data, including 60 services that reported zero couples at risk.
We have identified quality issues with the submitted data; therefore we recommend that regional performance is not compared. We share screening service level data with NHS England and NHS Improvement and we’re reviewing this KPI with the aim of improving data quality.
Quarter 2 performance
| Reporting period | 1 July to 30 September 2020 |
|---|---|
| Numerator | 153 |
| Denominator | 247 |
| Performance | 61.9% |
| Completeness of data | 100% |
| Region | Performance % |
|---|---|
| London | 54.7% |
| Midlands and East | 66.7% |
| North | 68.9% |
| South | 66.7% |
| England | 61.9% |
4. Newborn blood spot screening
4.1 KPI NB1: coverage of clinical commissioning group (CCG) responsibility at birth
National performance of NB1 in Q2 was 97.4%. The national trend graph below shows that NB1 performance has remained above the acceptable threshold of 95% since 1 April 2017.
All 135 CCGs submitted data, and 118 met the acceptable threshold of 95%.
Fifty-four CCGs reached the achievable threshold of 99%, and 14 of them reported performance of 100%.
Quarter 2 performance
| Reporting period | 1 July to 30 September 2020 |
|---|---|
| Numerator | 139,400 |
| Denominator | 143,171 |
| Performance | 97.4% |
| Completeness of data | 100% |
| Region | Performance % |
|---|---|
| London | 96.5% |
| Midlands and East | 98.8% |
| North | 97.3% |
| South | 96.3% |
| England | 97.4% |
4.2 KPI NB2: test – quality of the blood spot sample
National performance of NB2 in Q2 was 2.2%. The national trend graph below shows that NB2 performance has again increased above the acceptable threshold 2%. NB2 is a KPI where a lower performance is better.
Due to COVID-19, during Q1 (April to June) newborn screening laboratories were instructed to relax blood spot acceptance criteria on samples that would normally have been rejected and to accept day-four samples. Together these factors are likely to explain the reduced ‘avoidable repeat’ rate observed during Q1.
All 142 screening services submitted data in Q2.
Quarter 2 performance
| Reporting period | 1 July to 30 September 2020 |
|---|---|
| Numerator | 3,330 |
| Denominator | 152,228 |
| Performance | 2.2% |
| Completeness of data | 100% |
| Region | Performance % |
|---|---|
| London | 1.7% |
| Midlands and East | 1.8% |
| North | 3.0% |
| South | 2.2% |
| England | 2.2% |
4.3 KPI NB4: coverage of movers in
National performance of NB4 in Q2 was 90.6%. The national trend graph below shows that NB4 performance has remained below the acceptable threshold of 95% since 1 April 2017.
All 135 CCGs submitted data, and 46 met the acceptable threshold. Eighteen CCGs reached the achievable threshold of 99%.
Quarter 2 performance
| Reporting period | 1 July to 30 September 2020 |
|---|---|
| Numerator | 10,317 |
| Denominator | 11,386 |
| Performance | 90.6% |
| Completeness of data | 100% |
| Region | Performance % |
|---|---|
| London | 88.2% |
| Midlands and East | 91.6% |
| North | 92.2% |
| South | 91.4% |
| England | 90.6% |
5. Newborn hearing screening
5.1 KPI NH1: coverage
National performance of NH1 in Q2 was 97.8%. The national trend graph below shows that NH1 performance has dropped below the acceptable threshold of 98% in the last 3 quarters, although it has risen again in Q2.
During the COVID-19 pandemic, the newborn hearing screening programme (NHSP) encouraged services to continue screening where safe to do so in line with national standards and the NHSP technical guidance. However, in some areas screening was delayed due to COVID-19 and we have seen lower coverage as a result. This particularly affected community services where health visitors suspended home visits.
Quarter 2 performance
| Reporting period | 1 July to 30 September 2020 |
|---|---|
| Numerator | 146,770 |
| Denominator | 150,056 |
| Performance | 97.8% |
| Completeness of data | 100% |
| Region | Performance % |
|---|---|
| London | 96.8% |
| Midlands and East | 98.2% |
| North | 97.5% |
| South | 98.6% |
| England | 97.8% |
5.2 KPI NH2: diagnosis/intervention – time from screening outcome to attendance at an audiological assessment appointment
National performance of NH2 in Q2 was 87.4%. The national trend graph below shows that NH2 performance has dropped significantly below the acceptable threshold of 90% in Q4 2019 to 2020 and Q1 2020 to 20201, however in Q2 it has risen again.
During the COVID-19 pandemic in line with NHSE guidance, many audiology departments closed. This resulted in a delay in the assessment of babies referred from the screen in most services.
Quarter 2 performance
| Reporting period | 1 July to 30 September 2020 |
|---|---|
| Numerator | 3,432 |
| Denominator | 3,927 |
| Performance | 87.4% |
| Completeness of data | 100% |
| Region | Performance % |
|---|---|
| London | 85.4% |
| Midlands and East | 86.8% |
| North | 88.1% |
| South | 90.6% |
| England | 87.4% |
6. Newborn and infant physical examination screening
6.1 KPI NP1: coverage
National performance of NP1 in Q2 was 97.0%. The national trend graph below shows that NP1 performance has remained above the acceptable threshold of 95% since 1 July 2017.
One hundred and twenty-one out of 132 screening services met the acceptable threshold (one service did not submit data).
Seven services met the achievable threshold of 99.5%.
Quarter 2 performance
| Reporting period | 1 July to 30 September 2020 |
|---|---|
| Numerator | 145,126 |
| Denominator | 149,690 |
| Performance | 97.0% |
| Completeness of data | 99.2% |
| Region | Performance % |
|---|---|
| London | 96.4% |
| Midlands and East | 97.4% |
| North | 96.6% |
| South | 97.3% |
| England | 97.0% |
6.2 KPI NP2: diagnosis/intervention – timeliness of intervention for developmental dysplasia of the hip (DDH)
National performance of NP2 in Q2 was 33.2%. The national trend graph below shows that NP2 performance has remained below the acceptable threshold of 95% since 1 April 2017.
We recommend not to use NP2 data as a performance measure because of issues with data quality. Work to improve this data is ongoing through the newborn and infant physical examination (NIPE) data quality improvement project.
Quarter 2 performance
| Reporting period | 1 July to 30 September 2020 |
|---|---|
| Numerator | 325 |
| Denominator | 980 |
| Performance | 33.2% |
| Completeness of data | 99.2% |
| Region | Performance % |
|---|---|
| London | 38.5% |
| Midlands and East | 28.0% |
| North | 39.8% |
| South | 31.8% |
| England | 33.2% |